The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Broad neutralization coverage of HIV by multiple highly potent antibodies
Open accessAbstract
Broadly neutralizing antibodies against highly variable viral pathogens are much sought after to treat or protect against global circulating viruses. Here we probed the neutralizing antibody repertoires of four human immunodeficiency virus (HIV)-infected donors with remarkably broad and potent neutralizing responses and rescued 17 new monoclonal antibodies that neutralize broadly across clades. Many of the new monoclonal antibodies are almost tenfold more potent than the recently described PG9, PG16 and VRC01 broadly neutralizing monoclonal antibodies and 100-fold more potent than the original prototype HIV broadly neutralizing monoclonal antibodies. The monoclonal antibodies largely recapitulate the neutralization breadth found in the corresponding donor serum and many recognize novel epitopes on envelope (Env) glycoprotein gp120, illuminating new targets for vaccine design. Analysis of neutralization by the full complement of anti-HIV broadly neutralizing monoclonal antibodies now available reveals that certain combinations of antibodies should offer markedly more favourable coverage of the enormous diversity of global circulating viruses than others and these combinations might be sought in active or passive immunization regimes. Overall, the isolation of multiple HIV broadly neutralizing monoclonal antibodies from several donors that, in aggregate, provide broad coverage at low concentrations is a highly positive indicator for the eventual design of an effective antibody-based HIV vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [594]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Self-citationBrochet, X., Lefranc, M.-P., & Giudicelli, V. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn316 · Cited by 1,216
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
Richman, D. D., Wrin, T., Little, S. J., & Petropoulos, C. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630530100 · Cited by 1,200
Self-citationPrinted covalent glycan array for ligand profiling of diverse glycan binding proteins
Blixt, O., Head, S., Mondala, T., Scanlan, C., Huflejt, M. E., Alvarez, R., Bryan, M. C., Fazio, F., Calarese, D., Stevens, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407902101 · Cited by 1,101
Self-citationEfficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody
Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W. H. I., Sawyer, L. S. W., Hendry, R. M., Dunlop, N., Nara, P. L., et al. (1994) · Science · doi:10.1126/science.7973652 · Cited by 1,100
Self-citationLi, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10108-10125.2005 · Cited by 1,070
Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies
Haynes, B. F., Fleming, J., St. Clair, E. W., Katinger, H., Stiegler, G., Kunert, R., Robinson, J., Scearce, R. M., Plonk, K., Staats, H. F., et al. (2005) · Science · doi:10.1126/science.1111781 · Cited by 744
Binley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S., Katinger, H., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.13232-13252.2004 · Cited by 705
Self-citationParren, P. W. H. I., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P., & Burton, D. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.17.8340-8347.2001 · Cited by 662
Self-citationBridges, C. B., Thompson, W. W., Meltzer, M. I., Reeve, G. R., Talamonti, W. J., Cox, N. J., Lilac, H. A., Hall, H., Klimov, A., & Fukuda, K. (2000) · JAMA · doi:10.1001/jama.284.13.1655 · Cited by 651
Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T., Miiro, G., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00110-09 · Cited by 594
Self-citationHessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., Parren, P. W. H. I., Marx, P. A., & Burton, D. R. (2009) · Nature Medicine · doi:10.1038/nm.1974 · Cited by 546
Self-citationStiegler, G., Kunert, R., Purtscher, M., Wolbank, S., Voglauer, R., Steindl, F., & Katinger, H. (2001) · AIDS Research and Human Retroviruses · doi:10.1089/08892220152741450 · Cited by 517
Hessell, A. J., Rakasz, E. G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D. N., Koff, W. C., Watkins, D. I., & Burton, D. R. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000433 · Cited by 497
Self-citationTrkola, A., Pomales, A. B., Yuan, H., Korber, B., Maddon, P. J., Allaway, G. P., Katinger, H., Barbas, C. F., Burton, D. R., & Ho, D. D. (1995) · Journal of Virology · doi:10.1128/jvi.69.11.6609-6617.1995 · Cited by 480
Self-citationNeutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
Stamatatos, L., Morris, L., Burton, D. R., & Mascola, J. R. (2009) · Nature Medicine · doi:10.1038/nm.1949 · Cited by 430
Self-citationPolyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation
Mouquet, H., Scheid, J. F., Zoller, M. J., Krogsgaard, M., Ott, R. G., Shukair, S., Artyomov, M. N., Pietzsch, J., Connors, M., Pereyra, F., et al. (2010) · Nature · doi:10.1038/nature09385 · Cited by 427
Challenges in the development of an HIV-1 vaccine
Barouch, D. H. (2008) · Nature · doi:10.1038/nature07352 · Cited by 380
Walker, L. M., Simek, M. D., Priddy, F., Gach, J. S., Wagner, D., Zwick, M. B., Phogat, S. K., Poignard, P., & Burton, D. R. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001028 · Cited by 370
Self-citationThe challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus
Karlsson Hedestam, G. B., Fouchier, R. A. M., Phogat, S., Burton, D. R., Sodroski, J., & Wyatt, R. T. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1819 · Cited by 339
Self-citationWang, S.-K., Liang, P.-H., Astronomo, R. D., Hsu, T.-L., Hsieh, S.-L., Burton, D. R., & Wong, C.-H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712326105 · Cited by 287
Self-citationMartell, B. A., Orson, F. M., Poling, J., Mitchell, E., Rossen, R. D., Gardner, T., & Kosten, T. R. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.128 · Cited by 263
Pantophlet, R., Saphire, E. O., Poignard, P., Parren, P. W. H. I., Wilson, I. A., & Burton, D. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.642-658.2003 · Cited by 244
Self-citationImmunologic correlates of protection induced by vaccination
PLOTKIN, S. A. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200101000-00013 · Cited by 242
Nishimura, Y., Igarashi, T., Haigwood, N., Sadjadpour, R., Plishka, R. J., Buckler-White, A., Shibata, R., & Martin, M. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2123-2130.2002 · Cited by 161
HIV-1 and influenza antibodies: seeing antigens in new ways
Kwong, P. D., & Wilson, I. A. (2009) · Nature Immunology · doi:10.1038/ni.1746 · Cited by 130
Self-citationChallenges for structure-based HIV vaccine design
Schief, W. R., Ban, Y. A., & Stamatatos, L. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32832e6184 · Cited by 120
Protective immunity following vaccination: How is it defined?
Amanna, I. J., Messaoudi, I., & Slifka, M. K. (2008) · Human Vaccines · doi:10.4161/hv.4.4.5751 · Cited by 92
Herrera, G. A., Iwane, M. K., Cortese, M. M., Brown, C., Gershman, K., Shupe, A. K., Averhoff, F. M., Chaves, S. S., Gargiullo, P. M., & Bridges, C. B. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.129 · Cited by 88
SoDA2: a Hidden Markov Model approach for identification of immunoglobulin rearrangements
Munshaw, S., & Kepler, T. B. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq056 · Cited by 71
Willey, R. L., Nason, M., Nishimura, Y., Follmann, D. A., & Martin, M. A. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2009.0144 · Cited by 41
Research works printed but not linked: 1
- Plotkin, S. A. Orenstein, W. A. & Offit, P. A. Vaccines (Elsevier Health Sciences, Philadelphia, 2008)
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by specific antibodies, such as that seen on the surface of the HIV virion (507) (508) (509) 594) .”
BackgroundCo-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Liao, H.-X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., et al. (2013) · Nature · doi:10.1038/nature12053 · Cited by 988
Sanders, R. W., Derking, R., Cupo, A., Julien, J.-P., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003618 · Cited by 935
“trimer stability, the deletion of the MPER to improve homogeneity and solubility, and the introduction of a T332N substitution to create the epitopes for several bNAbs that depend on the presence of this glycan [5,6,24,30,31].”
BackgroundResultSelf-citationLocci, M., Havenar-Daughton, C., Landais, E., Wu, J., Kroenke, M. A., Arlehamn, C. L., Su, L. F., Cubas, R., Davis, M. M., Sette, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.031 · Cited by 868
“HIV bnAbs that can neutralize 70% or more of globally circulating HIV strains (Huang et al., 2012; Scheid et al., 2011; Walker et al., 2011; 2009) and can prevent infection in passive-transfer experiments using non-human primates (Moldt et al., 2012) have been characterized.”
Self-citationHIV infection: epidemiology, pathogenesis, treatment, and prevention
Maartens, G., Celum, C., & Lewin, S. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60164-1 · Cited by 830
Metadata
- Authors
- Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y., Moyle, M., Mitcham, J. L., Hammond, P. W., Olsen, O. A., Phung, P., Fling, S., Wong, C.-H., Phogat, S., Wrin, T., Simek, M. D., Principal Investigators, P. G., Koff, W. C., Wilson, I. A., Burton, D. R., & Poignard, P.
- Affiliations
- Scripps Research Institute (US)
- Theraclone Sciences (United States) (US)
- International AIDS Vaccine Initiative (US)
- Corresponding author
- Burton, Dennis R.
- Poignard, Pascal
- ORCID
- Venue
- Nature
- Published
- 2011-09
- Volume
- 477
- Issue
- 7365
- Pages
- 466-470
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3393110
- OpenAlex
- W2113236498
- Cited by
- 1,480
- References
- 32
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 51 · 2023: 54 · 2022: 69 · 2021: 81 · 2020: 82 · 2019: 92 · 2018: 107 · 2017: 134 · 2016: 109 · 2015: 144 · 2014: 154 · 2013: 157 · 2012: 139
- FWCI
- 60.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI033292, R01AI084817)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- HIV, broadly neutralizing antibodies, monoclonal antibodies, antibody repertoire, gp120, envelope glycoprotein, neutralization breadth, HIV vaccine design, passive immunization, antibody-based vaccines
- MeSH terms
- Antibodies, Monoclonal, Epitopes, Cell Line, Glycoproteins, Glycosylation, HIV, Humans, Immune Sera, Molecular Sequence Data, Neutralization Tests, HIV Antibodies, HIV Infections, AIDS Vaccines, Epitope Mapping, Human Immunodeficiency Virus Proteins, Antibodies, Neutralizing, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.